Search the Newsreel

Belite Bio (BLTE) Stock Looks Fully Valued After A 431% Run

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Belite Bio stock has delivered a very large 431.2% return over the past three years, while its valuation checks and current market multiples point to …

Benchmark reiterates Belite Bio stock rating on FDA priority review

Benchmark reiterated a Buy rating and a $217.00 price target for Belite Bio (NASDAQ:BLTE) after the FDA granted Priority Review to the company's New Drug Application for Tinlarebant, setting a PDUFA target date of February 12, 2027. The company plans a commercial launch in …

Mizuho raises Belite Bio stock price target to $220 on NDA progress

Yu-Hsin Lin Sells 365 Shares of Belite Bio (NASDAQ:BLTE) Stock

Belite Bio CEO Yu-Hsin Lin sold 365 shares of the company's stock for a total of $65,827.75, reducing his ownership by 0.21%. Despite the sale, analyst sentiment remains largely positive with a "Moderate Buy" consensus and a target price of $204.40, especially following the …

Mizuho Adjusts Price Target on Belite Bio to $220 From $215, Maintains Outperform Rating

Mizuho has increased its price target for Belite Bio (NASDAQ:BLTE) to $220 from $215, while reaffirming an Outperform rating on the stock. This adjustment reflects a continued positive outlook from the analyst firm. The biopharmaceutical company is focused on developing novel therapeutics for retinal …

Belite Bio Inc (BLTE) (Q2 2026) Earnings Call Highlights: FDA Priority Review and Strong Cash ...

This article first appeared on GuruFocus. Release Date: August 13, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Belite Bio Inc (NASDAQ:BLTE) received FDA acceptance of its New Drug Application (NDA) for Tinlarabant …

Belite Bio outlines February 12, 2027 PDUFA date for Tinlarebant in Stargardt disease following FDA priority review acceptance

Earnings Call Insights: Belite Bio (BLTE) Q2 2026 MANAGEMENT VIEW * Dr. Tom Lin (Chairman of the Board of Directors & CEO) framed the quarter around U.S. regulatory timing, saying, "the FDA has accepted our new drug application for Tinlarebant with priority review and …

Earnings call transcript: Belite Bio beats Q2 2026 EPS view as stock slips

Belite Bio reported a smaller-than-expected loss in Q2 2026, beating EPS estimates, but its stock still slipped. The company's lead candidate, tinlarebant for Stargardt disease, received priority review from the FDA, with a PDUFA date of February 12, 2027. Despite rising R&D and SG&A …

Belite Bio (BLTE) Is Up 12.9% After FDA Priority Review For Tinlarebant In Stargardt Disease

Belite Bio (BLTE) shares increased by 12.9% following the FDA's acceptance and Priority Review designation for its New Drug Application for tinlarebant, aimed at treating Stargardt Disease Type 1. The PDUFA target action date is set for February 12, 2027, and if approved, tinlarebant …

Belite Bio (NASDAQ:BLTE) Stock Price Down 7.2% - Should You Sell?

Belite Bio (NASDAQ:BLTE) stock declined 7.2% to $166.11 on Thursday, with trading volume below its average. Despite the drop, analysts have a "Moderate Buy" consensus rating with an average price target of $204.40. The company, a clinical-stage biotechnology firm, reported a narrower-than-expected quarterly loss …

Belite Bio (NASDAQ:BLTE) Posts Quarterly Earnings Results, Beats Estimates By $0.19 EPS

Belite Bio Q2 Net Loss Widens; FDA Sets PDUFA Date For Tinlarebant In February 2027

(RTTNews) - Belite Bio, Inc (BLTE), a clinical-stage drug development company, announced its financial results for the second quarter, reflecting a wider net loss. The company also provided an update on its New Drug Application (NDA) for tinlarebant for the treatment of Stargardt disease …

Belite Bio (NASDAQ: BLTE) wins FDA Priority Review and reports wider Q2 2026 loss

Belite Bio announced that the FDA accepted its New Drug Application for tinlarebant with Priority Review for treating Stargardt disease type 1, setting a PDUFA target action date of February 12, 2027. Despite this regulatory progress, the company reported a wider net loss of …

Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update

Belite Bio, Inc U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) with Priority Review for tinlarebant for the treatment of Stargardt disease type 1 (STGD1); Prescription Drug User Fee Act (PDUFA) target action date of February 12, 2027 Company presented …

Belite Bio stock price target raised to $214 by H.C. Wainwright on FDA review

H.C. Wainwright has increased its price target for Belite Bio (NASDAQ:BLTE) to $214 from $200, maintaining a Buy rating, after the FDA granted Priority Review to the New Drug Application for tinlarebant, a treatment for Stargardt disease type 1. The drug, which has shown …

Belite Bio lead asset granted FDA priority review (BLTE:NASDAQ)

The FDA has accepted Belite Bio's marketing application for its lead asset, tinlarebant, granting it priority review. This therapy targets an eye disease, and the FDA has set a target action date of February 12, 2027.

Belite Bio (NASDAQ: BLTE) wins FDA priority review for tinlarebant in Stargardt disease

Belite Bio announced that the FDA has accepted and granted Priority Review for its New Drug Application (NDA) for tinlarebant, aimed at treating Stargardt Disease Type 1 (STGD1). The FDA set a PDUFA date of February 12, 2027, for a decision. The NDA is …

Belite Bio Announces U.S. Food and Drug Administration Acceptance and Priority Review of New Drug Application for Tinlarebant for the Treatment of Stargardt Disease Type 1

Belite Bio announced that the FDA has accepted and granted Priority Review for its New Drug Application (NDA) for tinlarebant, aimed at treating Stargardt Disease Type 1 (STGD1). The FDA set a PDUFA date of February 12, 2027, and if approved, tinlarebant would be …

Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Receives Average Rating of "Moderate Buy" from Brokerages

Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) has received a consensus "Moderate Buy" rating from brokerages, with an average 12-month price target of $203.00. The company recently reported a quarterly loss of $0.34 per share, beating analyst estimates. Despite an insider selling 10,000 shares, institutional …

How Belite Bio Inc (BLTE) Affects Rotational Strategy Timing

This article analyzes Belite Bio Inc (BLTE) and its impact on rotational trading strategies. It highlights strong sentiment supporting an overweight bias, an exceptional risk-reward setup, and provides details on various institutional trading strategies including position trading, momentum breakout, and risk hedging, along with …

EpicQuest Education Group International Ltd (EEIQ) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for EpicQuest Education Group International Ltd (EEIQ), focusing on future EPS and revenue growth estimates. It includes current stock information, market capitalization, and a peer comparison for context. The forecast itself, detailing EPS, Revenue, and Net Profit EBIT, …

Elite UK REIT (SGX:MXNU) Stock Price Hinges On Debt And One Off Gains

The Manufacturers Life Insurance Company Purchases New Shares in Belite Bio, Inc. Sponsored ADR $BLTE

The Manufacturers Life Insurance Company has acquired a new stake of 19,600 shares in Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) during the first quarter, valued at approximately $3.125 million. Despite institutional investors owning only 0.53% of the stock, analysts maintain a positive "Moderate Buy" …

Elite Express Holding Regains Nasdaq Listing Compliance Status

Elite Express Holding Inc. Class A (ETS) has successfully regained compliance with Nasdaq's minimum bid price requirement. The company received a notice in October 2025 that its stock had fallen below $1.00 for 30 consecutive business days, but by August 6, 2026, it had …

Belite Bio to Host Webcast on August 13, 2026, to Discuss Second Quarter 2026 Financial Results

Belite Bio, a clinical-stage drug development company, announced it will host a webcast on Thursday, August 13, 2026, at 4:30 p.m. Eastern Time. The webcast will cover the company’s financial results and provide a business update for the second quarter ended June 30, 2026. …

EpicQuest Education Announces Four Agreements to Increase Enrollment at EduGlobal College and Davis University

EpicQuest Education Group International Limited (NASDAQ: EEIQ) has announced four new agreements aimed at increasing enrollment and revenue at its institutions, EduGlobal College and Davis University. These agreements include partnerships with Saint Paul International Academy for global high school recruiting and dual degree programs, …

Belite Bio, Inc (BLTE) Stock Price, News, Quote & History

This article provides a comprehensive overview of Belite Bio, Inc (BLTE), including its current stock price, recent performance, and key financial data. It details the company's biotechnology focus, highlighting its lead product candidate Tinlarebant in clinical trials for eye diseases and LBS-009 for liver …

Belite Bio will give a second-quarter business update Aug. 13

Belite Bio (NASDAQ: BLTE) announced it will host a webcast on August 13, 2026, to discuss its second-quarter 2026 financial results and provide a business update. The event will take place at 4:30 p.m. Eastern Time and a replay will be available for approximately …

Renaissance Technologies LLC Makes New Investment in Belite Bio, Inc. Sponsored ADR $BLTE

Renaissance Technologies LLC has initiated a new investment in Belite Bio, Inc. Sponsored ADR ($BLTE), acquiring 52,000 shares valued at approximately $8.3 million. Despite recent insider selling, analyst sentiment remains positive with a "Moderate Buy" rating and a consensus price target of $203. The …

Belite Bio presents updated phase 3 data on oral tinlarebant for Stargardt

Belite Bio recently announced positive secondary endpoint data from its phase 3 DRAGON trial of oral tinlarebant (LBS-008) for Stargardt disease type 1 (STGD1). The data, presented at the ASRS 2026 annual meeting, showed a statistically significant 35.7% slowing of DDAF lesion growth and …

Belite Bio (BLTE) Expected to Post Quarterly Earnings on Monday

BLTE|Belite Bio Inc|Price:159.920|Chg%:+7.480

This article provides a financial summary for Belite Bio Inc. (BLTE), detailing its stock performance, key financial indicators like EPS and Net Profit, and balance sheet information including assets, liabilities, and equity for various fiscal quarters. It also includes the latest earnings date and …

AME Elite Consortium Berhad Revenue Breakdown – MYX:AME